1. Introduction {#sec1}
===============

According to the European Association of Urology (EAU) guidelines on prostate carcinoma, radical prostatectomy (RP) is the standard treatment for stage T2N0M0 prostate cancer, equivalent to radiation therapy. For locally advanced prostate cancer, recommendations are less concise. In selected patients RP in combination with extended pelvic lymphadenectomy may be feasible. A study by Gontero et al. showed no relevant differences in the rate of comorbidities, only transfusion and lymphocele rate appeared more often compared to T2N0M0 prostate carcinoma. Cancer-specific survival (CSS) was 90% for T3-4, N0, M0 prostate cancer, and 99% for organ-confined cancer \[[@B1]\].

In lymph node positive prostate cancer after RP and adjuvant hormonal treatment 10-year CSS reaches 80% \[[@B2]\]. However, known lymph node metastasis remains a contraindication for most urologists for radical prostatectomy, and antihormonal treatment is initiated. Since then, the standing of radical prostatectomy as a treatment in this indication has been promoted by the findings of Engel et al., even in cases of suspected or proven lymph node metastasis. They were able to show that the survival of patients with lymph node metastasis was improved by radical prostatectomy when compared to patients who broke off surgery \[[@B3]\]. Adjuvant radiotherapy combined with hormonal treatment in lymph node involvement is advantageous when compared with hormonal treatment alone \[[@B4]\]. Preoperative prediction of lymph node involvement is challenging, especially in current-era prostate cancer with high percentage of low-risk prostate carcinoma that do not fit with the Roach formula, which overpredicts lymph node metastasis \[[@B5], [@B6]\].

We analysed a single-centre collective of patients suspected for ≥cT3 prostate carcinoma after radical prostatectomy and pelvic lymphadenectomy in order to establish the predictability of lymph node involvement by virtue of histopathological parameters.

2. Material and Methods {#sec2}
=======================

We retrospectively collected clinical and histopathological data of 34 patients who underwent RP for suspected ≥cT3 prostate cancer. Open surgery took place between 2007 and 2010 in a German single centre.

Suspect digital rectal examination (DRE), elevated PSA level, lower urinary tract symptoms (LUTS) or hydronephrosis led to the suspicion of prostate cancer, respectively. Diagnosis was assessed by ultrasound-guided prostate biopsy. Locally advanced stage was indicated by suspect digital rectal examination and confirmed by computed tomography (CT). There was no evidence of lymph node involvement or organ metastasis in CT assessment. Before surgical therapy all patients underwent bone scans without detection of skeletal metastasis. To reduce local tumour mass, five patients were neoadjuvantly treated antihormonally.

We assessed pT and pN stage, the share of positive margins (R1) and compared bioptic and specimen Gleason scores as well as the predictive value of these parameters with regard to the existence of lymph node metastasis.

3. Results and Discussion {#sec3}
=========================

3.1. Clinical and Histopathological Patient Data {#sec3.1}
------------------------------------------------

34 patients with a median age of 65 years (range 55--75 years) and with suspected locally advanced prostate carcinoma had a median PSA level of 23 ng/mL (range 5--141 ng/mL) at the time of diagnosis. The day prior to surgery median PSA level was 25 ng/mL, but some patients only had one PSA testing run before surgery. Four out of five patients who underwent neoadjuvant antihormonal therapy had no further preoperative PSA testing; one patient\'s PSA level decreased from 98 to 2 ng/mL.

The median Gleason score from the prostate biopsy was 8 (range 6--10) and from the prostatectomy specimen 9 \[[@B7]--[@B9]\]. Only in 44% Gleason score of prostate biopsy and specimen was identical; underestimation in prostate biopsy score of one to three points was detected in 41% of patients and overestimation of one score point in 15%. Patients showed pathological stage pT3a in 26%, pT3b in 59% and pT4 in 15%. For details see [Table 1](#tab1){ref-type="table"}. Residual tumour defined by cancer positive margin of the prostatectomy specimen was found in 76%. Neoadjuvant treatment seemed to have a protective effect, with positive margins in 60% of these patients whilst patients without preoperative antihormonal therapy showed residual tumour in 79% of cases. Whilst 85% of patients with positive margins had lymph node metastasis, only 50% of the patients without residual prostate tumour mass showed lymph node involvement ([Table 2](#tab2){ref-type="table"}). Median number of dissected lymph nodes was 15 (range 6--32), in the case of lymph node metastasis, and the median number of metastasis was 2 (range 1--10).

3.2. Discussion of Predictive Factors for the Existence of Lymph Node Metastasis {#sec3.2}
--------------------------------------------------------------------------------

In a multicentre series of 712 patients, Spahn et al. showed that PSA levels \>20 ng/mL were associated with organ-confined tumour in 33%, with Gleason score ≤6 in prostate biopsy in 8%, with negative surgical margins in 54%, and with no lymph node involvement in 85% of cases, respectively \[[@B7]\]. Patients with PSA levels \>20 ng/mL and suspected locally advanced prostate cancer had positive margins in 79% and lymph node invasion in 51% of cases. Our results confirmed these findings by showing residual tumour and lymph node metastasis in 76% of cases. Using the same series, Gontero et al. found that the PSA level was of prognostic relevance with 26% cured by surgery alone when PSA was 20--50 ng/mL but only about 7--9% with PSA \>50 ng/mL \[[@B8]\]. A single-centre analysis of more than 2 600 patients with locally advanced prostate cancer after RP and adjuvant androgen deprivation revealed the Gleason score to be the most important prognostic factor \[[@B9]\]. In our much smaller series we did not attempt to show cancer-specific survival, but for the prediction of T stage and lymph node involvement, the Gleason score was not the most obvious parameter. Evidence of residual tumour presence on the surgical margins in our patient collective was the most important predictive parameter for lymph node metastasis. 76% positive margins corresponded with 76% stage pN1. Patients with positive margins had synchronous lymph node metastasis in 85%, and negative margins were only associated in 50% with lymph node metastasization. Another study on a collective of high-risk prostate cancer (stage ≥pT3 in 89%) showed positive margins in 83% but only in 28% pN1 disease \[[@B10]\]. Oh et al. showed that positive margins in stage pT2 prostate cancer lead to a worse outcome, similar to that of patients with locally advanced prostate carcinoma \[[@B11]\].

4. Conclusions {#sec4}
==============

Alongside the Gleason score and pathological T stage, the presence of positive surgical margins is an important predictive factor in estimating lymph node involvement. Neoadjuvant antihormonal therapy does lead to a relevant reduction in the rate of positive margins, but not to a reduction in the rate of lymph node metastasis. As such, antihormonal and surgical treatment should be considered in combination for the therapy of locally advanced prostate cancer.

###### 

Characteristics of patients with locally advanced prostate carcinoma.

  No.   Age   PSA     GS biopsy   GS specimen   pT stage   pN stage
  ----- ----- ------- ----------- ------------- ---------- ----------
  1     60    77,3    6           7             pT3b       pN1
  2     66    36,0    6           7             pT3a       pN1
  3     68    30,2    6           7             pT3a       pN1
  4     62    58,0    6           8             pT3b       pN0
  5     64    35,6    6           9             pT3a       pN0
  6     59    60,0    6           9             pT3b       pN1
  7     60    31,5    7           7             pT3b       pN1
  8     65    52,0    7           7             pT3b       pN1
  9     70    56,0    7           7             pT3b       pN1
  10    74    17,8    7           8             pT3b       pN0
  11    63    21,4    7           8             pT3b       pN1
  12    75    14,2    7           9             pT3b       pN1
  13    55    5,8     7           9             pT4        pN0
  14    61    100,0   7           9             pT3a       pN0
  15    63    14,1    7           9             pT4        pN1
  16    62    47,0    8           7             pT3b       pN1
  17    74    23,3    8           7             pT3a       pN1
  18    63    73,0    8           8             pT3b       pN1
  19    68    11,5    8           8             pT3a       pN0
  20    71    15,2    8           8             pT3a       pN0
  21    70    9,5     8           8             pT3b       pN1
  22    71    141,0   8           9             pT3b       pN1
  23    65    138,0   8           9             pT4        pN1
  24    64    34,7    9           8             pT4        pN1
  25    70    7,2     9           9             pT3a       pN1
  26    69    14,6    9           9             pT3b       pN1
  27    60    13,0    9           9             pT3b       pN1
  28    70    100,0   9           9             pT3b       pN1
  29    58    25,0    9           9             pT3a       pN0
  30    67    100,0   9           9             pT3b       pN1
  31    61    22,0    9           9             pT3b       pN1
  32    68    2,2     9           9             pT3b       pN1
  33    56    15,1    10          9             pT3b       pN1
  34    70    15,0    10          9             pT4        pN1

GS: Gleason score.

###### 

Association of positive margins with lymph node metastasis.

  No.   Age   Neoadj. HT   R stage   pN stage
  ----- ----- ------------ --------- ----------
  1     60    No           R1        pN1
  2     66    No           R1        pN1
  3     68    No           R1        pN1
  4     62    No           R1        pN0
  5     64    No           R0        pN0
  6     59    No           R1        pN1
  7     60    Yes          R0        pN1
  8     65    No           R1        pN1
  9     70    No           R1        pN1
  10    74    No           R0        pN0
  11    63    No           R1        pN1
  12    75    No           R1        pN1
  13    55    No           R1        pN0
  14    61    Yes          R1        pN0
  15    63    No           R1        pN1
  16    62    Yes          R0        pN1
  17    74    No           R0        pN1
  18    63    No           R1        pN1
  19    68    No           R0        pN0
  20    71    No           R0        pN0
  21    70    No           R1        pN1
  22    71    No           R1        pN1
  23    65    No           R1        pN1
  24    64    No           R1        pN1
  25    70    No           R0        pN1
  26    69    No           R1        pN1
  27    60    No           R1        pN1
  28    70    Yes          R1        pN1
  29    58    No           R1        pN0
  30    67    No           R1        pN1
  31    61    No           R1        pN1
  32    68    Yes          R1        pN1
  33    56    No           R1        pN1
  34    70    No           R1        pN1

HT: antihormonal treatment.
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